MXPA03000937A - Proteina reguladora del hierro (irp-2) como un diagnostico para enfermedades neurodegenerativas. - Google Patents

Proteina reguladora del hierro (irp-2) como un diagnostico para enfermedades neurodegenerativas.

Info

Publication number
MXPA03000937A
MXPA03000937A MXPA03000937A MXPA03000937A MXPA03000937A MX PA03000937 A MXPA03000937 A MX PA03000937A MX PA03000937 A MXPA03000937 A MX PA03000937A MX PA03000937 A MXPA03000937 A MX PA03000937A MX PA03000937 A MXPA03000937 A MX PA03000937A
Authority
MX
Mexico
Prior art keywords
irp
neurodegenerative disease
fragments
proteins
diagnostic
Prior art date
Application number
MXPA03000937A
Other languages
English (en)
Spanish (es)
Inventor
Wayne J Kelln
Original Assignee
Univ Loma Linda Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Loma Linda Med filed Critical Univ Loma Linda Med
Publication of MXPA03000937A publication Critical patent/MXPA03000937A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MXPA03000937A 2000-08-04 2001-08-06 Proteina reguladora del hierro (irp-2) como un diagnostico para enfermedades neurodegenerativas. MXPA03000937A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22286300P 2000-08-04 2000-08-04
PCT/US2001/024747 WO2002012284A2 (en) 2000-08-04 2001-08-06 Iron regulating protein-2 (irp-2) as a diagnostic for neurodegenerative disease

Publications (1)

Publication Number Publication Date
MXPA03000937A true MXPA03000937A (es) 2004-08-02

Family

ID=22834032

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03000937A MXPA03000937A (es) 2000-08-04 2001-08-06 Proteina reguladora del hierro (irp-2) como un diagnostico para enfermedades neurodegenerativas.

Country Status (9)

Country Link
US (4) US20020165349A1 (enExample)
EP (1) EP1355933A2 (enExample)
JP (1) JP2004506420A (enExample)
CN (1) CN100535004C (enExample)
AU (1) AU2001284742A1 (enExample)
CA (1) CA2417310A1 (enExample)
MX (1) MXPA03000937A (enExample)
RU (1) RU2003105882A (enExample)
WO (1) WO2002012284A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP2298311B1 (en) 1999-01-13 2012-05-09 Bayer HealthCare LLC w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
DK1478358T3 (da) 2002-02-11 2013-10-07 Bayer Healthcare Llc Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese
ATE404877T1 (de) * 2002-08-27 2008-08-15 Kennedy Krieger Inst Magnetische rezonanzbildgebung des mikrovaskulären blutvolumens
UY28213A1 (es) 2003-02-28 2004-09-30 Bayer Pharmaceuticals Corp Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
EP1636585B2 (en) 2003-05-20 2012-06-13 Bayer HealthCare LLC Diaryl ureas with kinase inhibiting activity
PL1663978T3 (pl) 2003-07-23 2008-04-30 Bayer Healthcare Llc Fluoropodstawiony omega-karboksyarylodifenylomocznik do leczenia i profilaktyki chorób i stanów
US7838524B2 (en) * 2004-04-30 2010-11-23 Bayer Healthcare Llc Substituted pyrazolyl urea derivatives useful in the treatment of cancer
JP4653542B2 (ja) * 2005-04-06 2011-03-16 株式会社東芝 画像処理装置
CN100448481C (zh) * 2006-06-22 2009-01-07 中国科学院遗传与发育生物学研究所 xCT蛋白及其编码基因的新用途
CN102308214B (zh) * 2008-12-12 2014-06-25 贝克曼考尔特公司 包含未偶联的藻胆蛋白的多色流式细胞术组合物
US8580230B2 (en) * 2009-02-23 2013-11-12 Kent State University Materials and methods for MRI contrast agents and drug delivery
EP2253716A1 (en) * 2009-05-15 2010-11-24 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Diagnostic methods for the prognosis of a brain tumor
EP2642289A1 (en) 2012-03-20 2013-09-25 Sensirion AG Portable electronic device
US9259357B2 (en) 2014-04-16 2016-02-16 Loma Linda University Composition, preparation, and use of chitosan shards for biomedical applications
CA2981533A1 (en) * 2015-04-02 2016-10-06 Crc For Mental Health Ltd Method for predicting risk of cognitive deterioration
WO2018148788A1 (en) * 2017-02-17 2018-08-23 Crc For Mental Health Ltd Method for predicting risk and rate of amyloid deposition and plaque formation
IT201700105483A1 (it) * 2017-09-21 2019-03-21 Braindtech S R L Metodo per la diagnosi e la prognosi di patologie neurodegenerative e neuroinfiammatorie
JP6737995B2 (ja) * 2018-11-29 2020-08-12 株式会社Ｒｅｓｖｏ 精神疾患発症危険状態の診断用バイオマーカー
CN114446392B (zh) * 2022-01-21 2024-01-30 华东理工大学 确认蛋白质与核酸适配体结合时的关键精氨基酸残基位点的方法
CN114457067B (zh) * 2022-02-10 2024-10-25 中国科学院天津工业生物技术研究所 一种低成本快速去除dna合成中错误的方法
CN117417999B (zh) * 2023-11-27 2025-07-25 河南省人民医院 一种与ireb2基因相关的snp分子标记及其应用

Also Published As

Publication number Publication date
US20020165349A1 (en) 2002-11-07
US20100041060A1 (en) 2010-02-18
RU2003105882A (ru) 2005-01-20
US20050260669A1 (en) 2005-11-24
CN100535004C (zh) 2009-09-02
WO2002012284A2 (en) 2002-02-14
EP1355933A2 (en) 2003-10-29
CA2417310A1 (en) 2002-02-14
US20080020393A1 (en) 2008-01-24
AU2001284742A1 (en) 2002-02-18
CN1556815A (zh) 2004-12-22
JP2004506420A (ja) 2004-03-04
WO2002012284A3 (en) 2003-08-21

Similar Documents

Publication Publication Date Title
WO2002012284A3 (en) Iron regulating protein-2 (irp-2) as a diagnostic for neurodegenerative disease
BR9708470A (pt) Agentes de contraste bioativados para formação de imagem para diagnósticos
WO2005018424A3 (en) Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits
WO2005047484A3 (en) Biomarkers for alzheimer's disease
ATE364623T1 (de) Peptid zur diagnose und therapie der alzheimer- demenz
EP1361229A3 (en) Use of Tyrosine Kinase (PYK2) to produce antibodies
EA200300637A1 (ru) Гуманизированные антитела, распознающие бета-амилоидный пептид
MXPA03010144A (es) Proteinas de agutinacion al peptido beta-amiloide y polinucleotidos que las codifican.
EP1571970A4 (en) DIAGNOSIS AND MONITORING OF DISEASES
WO2002050277A3 (en) Protein and nucleic acids encoding same
WO2002046767A3 (en) Diagnosis and treatment of alzheimer's disease
WO2001062891A3 (en) 207 human secreted proteins
GB0130305D0 (en) Compounds for imaging alzheimers disease
EP1270588A4 (en) NEW COLLAGEN-LIKE PROTEIN CLAC, ITS PRECURSORS AND GENES CODING THEREFOR
WO2004003563A3 (en) Diagnostic and therapeutic use of ensadin-0581 gene and protein for neurodegenerative diseases
WO2002079398A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
DE60125148D1 (de) Fctrx genannte proteine und dafür kodierende nuklein säure
WO2006134128A3 (en) Diagnostic and therapeutic target adarb2 proteins for neurodegenerative diseases
WO2001074851A3 (en) Novel proteins and nucleic acids encoding same
WO2002099116A8 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2002083841A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2006029838A3 (en) Secreted polypeptide species involved in alzheimer’s disease
WO2002050276A3 (en) Proteins and nucleic acids encoding same
WO2003052377A9 (en) 41 human secreted proteins
WO2002040539A3 (en) Gpcr-like protein and nucleic acids encoding same